Clinical Trial Update: Effect of Intranasal Oxytocin on Dysphagia in Children and Adolescents With Prader-Willi Syndrome [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating intranasal oxytocin for dysphagia in children and adolescents with Prader-Willi syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prader-willi Syndrome

Drugs mentioned

• intranasal oxytocin (oxytocin)

Snippet

Sponsor: University Hospital, Toulouse | Conditions: Prader-Willi Syndrome | Phase 2, Phase 3 | Status: COMPLETED